A5064309201- Cardiac Valve Diseases and Treatments
- Aortic Disease and Treatment Approaches
- Infective Endocarditis Diagnosis and Management
- Cardiac and Coronary Surgery Techniques
- Cardiac, Anesthesia and Surgical Outcomes
- Cardiac Structural Anomalies and Repair
- Aortic aneurysm repair treatments
- Cardiovascular Function and Risk Factors
- Congenital Heart Disease Studies
- Acute Myocardial Infarction Research
- Coronary Interventions and Diagnostics
- Cardiac Imaging and Diagnostics
- Hip and Femur Fractures
- Mechanical Circulatory Support Devices
- Antimicrobial Resistance in Staphylococcus
- Connective tissue disorders research
- Cardiac Ischemia and Reperfusion
- Cardiac Arrhythmias and Treatments
- Vascular anomalies and interventions
- Protease and Inhibitor Mechanisms
- Infectious Aortic and Vascular Conditions
- Elasticity and Material Modeling
- Heart Failure Treatment and Management
- Streptococcal Infections and Treatments
- Antiplatelet Therapy and Cardiovascular Diseases
Fondazione Toscana Gabriele Monasterio
2015-2024
Regione Toscana
2022-2023
Fundación Juan March
2023
IRCCS San Camillo Hospital
2011-2022
Hospital Clínic de Barcelona
2020
Scan Foundation
2018
Ospedale generale di zona San Camillo Treviso
2016
Klinikum Arnsberg
2015
Società Italiana di Cardiologia
2015
Ospedale Sant'Anna
2014
The aim of our study was to evaluate the early outcomes and 1-year survival patients undergoing minimally invasive aortic valve replacement with Perceval S sutureless for severe stenosis.From March 2010 2013, 281 high-risk underwent through either right anterior minithoracotomy (n = 164) or upper ministernotomy 117) at 2 cardiac centers.The overall in-hospital mortality 0.7% (2 patients). median cardiopulmonary bypass crossclamp time 81 minutes (interquartile range, 68-98) 48 37-60),...
Background: Infective endocarditis (IE) is marked by a heightened risk of embolic events (EEs), uncontrolled infection, or heart failure (HF). Methods: Patients with IE and surgical indication were enrolled from October 2015 to December 2018. The primary endpoint consisted composite major adverse (MAEs) including all-cause death, hospitalizations, relapses. secondary was death. Results: A total 102 patients (66 ± 14 years) enrolled: 50% on prosthesis, 33% IE-associated (IE-aHF), 38.2% EEs....
Objective: Perceval sutureless valve (Corcym, Saluggia, Italy) has been in clinical use for more than 15 years. The aim of this study is to report and hemodynamic performance from a real-world registry patients who underwent aortic replacement (AVR) with Perceval, comparing outcomes minimally invasive (MICS) versus full sternotomy (FS) settings. Methods: This prospective international enrolled 1,652 implanted 55 institutions 2011 2021. Patients isolated AVR were analyzed by MICS FS...
Background: A minimally invasive approach (MIA) reduces mortality and morbidity in patients referred for aortic valve replacement (AVR). Sutureless technology facilitates a MIA. We describe our experience with the sutureless Perceval (LivaNova, Italy) bioprosthesis through right anterior mini-thoracotomy (RAMT) approach. Methods: Between March 2011 October 2019, 1,049 underwent AVR bioprosthesis. Five hundred three (48%) were operated RAMT second intercostal space. Considering only isolated...
Perceval sutureless valve has been in clinical use for >15 years. The aim of this study is to report the real-word and haemodynamic performance from SURE-aortic replacement international prospective registry patients who underwent aortic with valve.From 2011 2021, 55 institutions received a valve. Postoperative, follow-up, echocardiographic outcomes were analysed.A total 1652 included; mean age was 75.3 ± 7.0 years (53.9% female); EuroSCORE II 4.1 6.3. Minimally invasive approach performed...
The Perceval S bioprosthesis (21 and 23 mm) was approved for clinical use in December 2010 it is now routinely used. This suggested the treatment of patients undergoing minimally-invasive surgery reasons safety reduction implantation time. Here we describe minimally invasive cardiac surgery.
The Perceval S sutureless valve prosthesis has recently been introduced as a new biological aortic prosthesis, but specific learning curve is required, for every cardiac surgical centre dealing with technique. After the removal of stenotic valve, prosthetic correctly positioned within mildly decalcified annulus. When supra-annular malposition occurs, due to an excessively rapid release in aorta or incomplete annular visualization, can safely be removed even after balloon dilation. procedure...
Sutureless aortic bioprosthesis implantation is an alternative technique in high-risk patients undergoing valve replacement with a possible reduction the extracorporeal circuit time and reliable haemodynamic features. A 3F Enable (ATS Medical-Medtronic, Inc., Minneapolis, MN, USA) has shown very good results. We report first upward displacement of three months post implantation.
Aortic valve replacement (AVR) in patients with severe aortic root calcification is technically a very difficult procedure which requires long cardiopulmonary bypass (CPB) time, especially undergoing complex procedures such as multivalve or and coronary surgery. We report case of successful AVR an innovative approach patient extensively calcified concomitant tricuspid regurgitation who underwent mitral 20 years ago.
We describe long-term clinical and echocardiographic outcomes in the largest single-centre cohort of patients who underwent aortic valve replacement (AVR) with sutureless Perceval (CorCym, Italy) bioprosthesis.Between March 2011 2021, 1157 AVR bioprosthesis implantation. Mean age was 77 ± 6 years (range: 46-89 years) mean EuroSCORE II 6.7 3.2% 1.7-14.2%). Concomitant procedures were performed 266 (23%).Thirty-day mortality 1.38% (16/1157). Eight hundred twenty 891 (92%) isolated AVRs...
Sutureless aortic bioprostheses are increasingly being used to provide shorter cross-clamp time and facilitate minimally invasive valve replacement. As the use of sutureless valves has increased over past decade, we begin encounter their degeneration. We describe clinical outcomes technical aspects in patients with degenerated Perceval (CorCym, Italy) bioprosthesis treated valve-in-valve transcatheter replacement (VIV-TAVR).Between March 2011 2023, 1310 underwent (AVR) implantation. Severe...
To evaluate the influence of patient-prosthesis mismatch (PPM) on survival, and quality life (QOL) after aortic valve replacement (AVR) in elderly patients with small prosthesis size.Between 2005 2010, 142 older than 65 years were discharged from hospital AVR 19 or 21 mm for stenosis. Their median age was 79 (range 66 to 91). Prosthesis effective orifice area (EOA) derived continuity equation PPM defined as an indexed EOA (IEOA) < 0.85 cm(2)/m(2). Patients having IEOA 0.75 cm(2)/m(2) 0.60...